According to research, it was found that people who stop taking these weight loss drugs can support most of the weight they have lost because they can want or obtain the desired drug. We have seen that this is not uncommon because other drugs lose their efficacy once they reach the "pooping" point, as medical professionals have said.
What is even more disappointing about weight loss drugs is that people who continue to take them (at $1,000 per month) eventually reach a plateau where their bodies no longer lose weight. At this point, according to some experts, the full action of this drug is not known, but we know that the body has a predetermined point and the drug works to prevent it.
Perhaps it is a natural defense mechanism we have. Some people call it a form of physical self-regulation imposed by the body.
In the short term, weight loss can occur because the basal metabolism slows down. This means that the body needs less energy to do the same job, so the food you eat does not burn quickly. Weight gain may start again. Your body may also try to revert to the previous weight by changing hormone levels that affect appetite and basal metabolism. You can also change the amount of water you drink. This process is attractive, powerful, and frustrating for those who want to lose weight.
People voluntarily stop taking this drug due to noticeable side effects when it is first used in type 2 diabetes patients. The most common reasons provided by doctors for discontinuing GLP-1 drugs to patients who stopped taking them were that the patients could not control their blood sugar well (45.6%), were sick (43.8%), or had gastrointestinal (GI) issues. There were other side effects such as constipation or diarrhea. Patients discontinued the drug because they preferred oral medication over injectable drugs.
According to one study, the average annual treatment cost for people before taking Wegovy or similar drugs was $12,371. After starting drug therapy, the average treatment cost increased by 59% annually to $19,657. Non-diabetic patients...